2858-LB: Icovamenib, a Menin Inhibitor, Improves Endogenous Insulin Secretion in Type 1 Diabetes: Results from the COVALENT-112 Study
Diabetes · 05.06.2026 · 75 (Supplement_1)
DOI: 10.2337/db26-2858-lb ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von JUAN P. FRIAS. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Introduction and Objective: Loss of functional pancreatic beta-cell mass in T1D leads to progressive decline in endogenous insulin secretion. Therapies restoring or improving beta-cell function remain a major unmet need. Icovamenib is an oral small-molecule menin inhibitor that modulates pathways involved in insulin secretion. COVALENT-112 evaluated the effect of icovamenib on insulin secretion in T1D.
Methods
COVALENT-112 is a Phase 2, randomized, multicenter study evaluating icovamenib in adults with T1D. Participants were enrolled into 2 cohorts based on time since diagnosis and baseline endogenous insulin secretion. Cohort-1: participants diagnosed ≤3 years with measurable C-peptide during MMTT. Cohort-2: participants diagnosed >3 to ≤15 years with minimal C-peptide. Participants received 100mg or 200mg icovamenib once-daily for 12 weeks. Endogenous insulin secretion was assessed by MMTT and C-peptide AUC was calculated.
Results
Thirty-seven participants were enrolled; only those receiving ≥80% of planned dosing were included in the analysis per protocol. In Cohort-1 (N=11), participants receiving 100mg (N=6) showed C-peptide AUC −7% from baseline at Week 12 and −31% at Week 52. Participants receiving 200mg (N=5) showed +56% C-peptide AUC at Week 12 and −7% from baseline at Week 52. In Cohort-2 (N=9), C-peptide AUC remained stable during dosing; participants receiving 100mg (N=5) showed −29% at Week 52, while those receiving 200mg (N=4) showed −3% at Week 52. Icovamenib was generally well tolerated with no serious treatment-emergent adverse events. Two participants in Cohort-2 receiving 200mg discontinued treatment due to elevated liver enzymes. All other safety events were mild or moderate.
Conclusion
Icovamenib treatment in individuals with T1D appeared to slow the decline in endogenous insulin secretion observed in natural history studies, with a dose-response trend. Despite the small sample size, these findings suggest menin inhibition may enhance residual beta-cell function. Disclosure J.P. Frias: Employee; Ended; Biomea Fusion.
Zitieren
APA
FRIAS, J. P. (2026). 2858-LB: Icovamenib, a Menin Inhibitor, Improves Endogenous Insulin Secretion in Type 1 Diabetes: Results from the COVALENT-112 Study. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-2858-lb
Vancouver
FRIAS JP. 2858-LB: Icovamenib, a Menin Inhibitor, Improves Endogenous Insulin Secretion in Type 1 Diabetes: Results from the COVALENT-112 Study. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-2858-lb
BibTeX
@article{FRIAS2026,
author = {FRIAS, JUAN P.},
title = {2858-LB: Icovamenib, a Menin Inhibitor, Improves Endogenous Insulin Secretion in Type 1 Diabetes: Results from the COVALENT-112 Study},
journal = {Diabetes},
year = {2026},
volume = {75},
number = {Supplement_1},
doi = {10.2337/db26-2858-lb}
}
EUVIMED